SCHEMBL3883500

SCHEMBL3883500

O=C(O)CCCOc1cccc(NC(=O)C(=O)c2c(-c3ccccc3)cc3ccccn23)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.57
ALDH1A1 P00352 5/20 0.57
MAPT P10636 4/20 0.57
LMNA P02545 3/20 0.57
THRB P10828 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 4/20 0.51
FABP1 P07148 1/20 0.44
FFAR4 Q5NUL3 5/20 0.43
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FFAR1 O14842 2/20 0.41
PLA2G1B P04054 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646578 0.89 MAPT (0.60) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL3883300 0.88 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1646696 0.87 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1644775 0.85 MAPT (0.61) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1644516 0.84 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1647753 0.83 MAPT (0.59) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1644750 0.81 L3MBTL1 (0.69) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1645406 0.80 ALDH1A1 (0.65) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1647290 0.80 MAPT (0.64) SMN1; SMN2ALDH1A1MAPTLMNATHRB
SCHEMBL1647401 0.79 MAPT (0.66) SMN1; SMN2ALDH1A1MAPTLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885ALDH1A1 510/4885MAPT 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.